Secondaries announced 1.05.2016
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Adamas Pharmaceuticals, Inc. Symbol: ADMS Price: Last trade $27.91 Trade Date: 1/7 Shares: 2.5 million Underwriter(s) Cowen & Co., Piper Jaffray[…]